This article needs additional citations for verification. (July 2012) |
Clinical data | |
---|---|
Trade names | Bisolvon, others |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 75–80% |
Metabolism | Extensive hepatic |
Metabolites | Ambroxol, others |
Elimination half-life | 12 hr |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.622 |
Chemical and physical data | |
Formula | C14H20Br2N2 |
Molar mass | 376.136 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Bromhexine is a mucolytic drug used in the treatment of respiratory disorders associated with viscid or excessive mucus.[1] It was developed in the research laboratory of Boehringer Ingelheim in the late 1950s as an active ingredient for pharmaceutical use, patented in 1961, introduced in 1963 under the trademark of Bisolvon® and came into medical use in 1966.[2]